Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial
Source: View publication →
In patients with acute coronary syndromes undergoing invasive management, radial artery access did not reduce the primary composite endpoint of death, myocardial infarction, stroke, or non-CABG-related major bleeding at 30 days compared to femoral access, though it significantly lowered rates of major vascular access site complications.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RIVAL trial established that radial artery access is a safe and effective alternative to the traditional femoral approach for patients with acute coronary syndromes, offering a clear advantage in reducing vascular access site complications without compromising procedural efficacy, particularly in high-volume settings.
Historical Context
Prior to RIVAL, the debate regarding radial versus femoral access was largely guided by observational studies and small randomized trials that suggested radial access might reduce bleeding. RIVAL was the first large-scale, international randomized controlled trial designed to definitively compare these strategies for primary clinical outcomes in an acute coronary syndrome population.
Guided Discussion
High-yield insights from every perspective
Anatomically, why does the radial artery approach significantly reduce the risk of major vascular complications compared to the femoral approach, as demonstrated in the RIVAL trial?
Key Response
The radial artery is superficial, smaller in caliber, and sits directly over the distal radius (a bony structure), making it easily compressible in the event of bleeding. In contrast, the femoral artery is deeper, larger, and located near the retroperitoneal space; bleeding at this site can be occult and difficult to tamponade, leading to the higher rates of hematomas and pseudoaneurysms observed in the femoral arm of the study.
The RIVAL trial showed no significant difference in the primary composite endpoint for the total population but showed a benefit in the STEMI subgroup. How should this influence your choice of access site in a patient presenting with an inferior STEMI versus NSTE-ACS?
Key Response
While the overall trial was neutral, the pre-specified subgroup analysis for STEMI patients suggested a reduction in death, MI, or stroke. In STEMI, where patients are heavily anticoagulated and require urgent reperfusion, the bleeding benefit of radial access may translate into a mortality benefit (as later confirmed in trials like MATRIX). Therefore, radial access is preferred in STEMI when the operator is proficient, whereas in NSTE-ACS, the choice may be more flexible based on operator expertise.
The RIVAL trial demonstrated a significant interaction between center radial volume and the primary endpoint. What are the implications of this 'volume-outcome' relationship for the global generalizability of radial-first strategies?
Key Response
The trial found that benefit from radial access was primarily realized in high-volume radial centers (p=0.021 for interaction). This suggests that the 'radial advantage' is not intrinsic to the route alone but is highly dependent on operator proficiency. For a fellow, this emphasizes that the learning curve for radial access (estimated at 30-50 cases for basic proficiency) must be overcome before the theoretical benefits in safety and mortality can be clinically realized in high-risk ACS patients.
RIVAL failed to meet its primary composite endpoint of death, MI, stroke, or non-CABG bleeding, yet it is considered a landmark trial that catalyzed the shift to radial access. How do you reconcile a statistically neutral primary endpoint with a change in standard of care?
Key Response
The shift occurred because radial access demonstrated a clear, significant reduction in major vascular complications (1.4% vs 3.7%, p<0.0001) and was preferred by patients for earlier mobilization. In clinical practice, if two procedures offer similar hard outcomes (death/MI) but one significantly reduces procedural morbidity and improves patient experience, the safer profile dictates the standard of care, especially as subsequent meta-analyses and trials (MATRIX, RIVAL-STEMI) eventually showed mortality benefits in high-risk subsets.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The RIVAL trial utilized a non-CABG-related major bleeding definition. How does the choice of bleeding scale (e.g., ACUITY, GUSTO, or TIMI) impact the sensitivity of a trial to detect differences between radial and femoral access, and why might this explain the neutral primary result?
Key Response
The primary endpoint in RIVAL used a composite that included bleeding, but different bleeding definitions vary in their inclusion of hematomas or access-site complications. RIVAL used a relatively strict 'major' bleeding definition. If a trial uses a more sensitive scale (like BARC or ACUITY) that captures smaller but clinically relevant access-site bleeds, the statistical power to find a difference increases. The neutral result in RIVAL's primary endpoint may partly stem from the dilution of the bleeding benefit by the harder endpoints of death and MI in a non-optimized (lower volume) population.
RIVAL reported a 7.6% crossover rate from the radial to the femoral group, compared to only 2.0% from femoral to radial. How does this high crossover rate affect the interpretation of the 'Intention-to-Treat' (ITT) analysis, particularly regarding the safety outcomes?
Key Response
In an ITT analysis, crossovers from radial to femoral are still analyzed in the radial group. Since these patients actually received the femoral procedure—often after a failed radial attempt—they are exposed to the higher risks of the femoral site. This 'dilutes' the perceived safety benefit of the radial approach. A reviewer would flag this as a potential bias toward the null, suggesting that the radial approach might actually be even safer than the ITT results indicate, although the Per-Protocol analysis usually helps clarify this.
How did the RIVAL trial's subgroup findings regarding STEMI and operator volume influence the evolution of the Class of Recommendation for radial access in subsequent ESC and ACC/AHA guidelines?
Key Response
RIVAL provided the first large-scale randomized evidence that radial access was non-inferior and safer regarding local complications. Based on RIVAL and subsequent trials like MATRIX, the ESC guidelines moved to a Class I (Level A) recommendation for radial access in ACS. The ACC/AHA guidelines also elevated radial access to Class I, specifically highlighting that the benefit is most pronounced in STEMI and when performed by 'radial-expert' operators, directly reflecting the RIVAL subgroup interactions.
Clinical Landscape
Noteworthy Related Trials
RFAVI Trial
Tested
Radial artery access
Population
Patients undergoing PCI
Comparator
Femoral artery access
Endpoint
Vascular complications
MATRIX Trial
Tested
Radial access
Population
Patients with acute coronary syndromes undergoing invasive management
Comparator
Femoral access
Endpoint
Major adverse cardiovascular events (MACE) and net adverse clinical events (NACE)
SAFARI-STEMI Trial
Tested
Radial access
Population
Patients with ST-segment elevation myocardial infarction
Comparator
Femoral access
Endpoint
All-cause mortality, MI, or stroke at 30 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis